<DOC>
	<DOCNO>NCT01899053</DOCNO>
	<brief_summary>This study multicenter , open-label , phase 1b trial MLN0128 ( oral mTORC1/2 inhibitor ) combination MLN1117 ( oral inhibitor PI3K ( alpha ) isoform ) administer adult patient advance nonhematological malignancy .</brief_summary>
	<brief_title>Phase 1b Study MLN0128 Combination With MLN1117 Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male female patient 18 year old Patients must diagnosis documented disease progression solid tumor malignancy , exclude primary brain tumor , standard , curative , life prolong treatment exist longer effective Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Female subject postmenopausal least 1 year prior screening . For woman childbearing potential agree practice 2 effective method contraception , agree practice true abstinence Male subject must agree practice effective barrier contraception entire study treatment period 30 day last dose study drug practice true abstinence Voluntary write consent Suitable venous access Patients must block banked tumor tissue and/or fresh tumor tissue least 10 unstained slide available sent central laboratory Clinical laboratory value specify protocol Patients must radiographically clinically evaluable tumor Female patient lactate breastfeed positive serum pregnancy test Screening period positive urine pregnancy test Day 1 first dose study drug Any serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment Treatment investigational product within 30 day first dose study drug Previous treatment MLN1117 and/or MLN0128 ; previous treatment dual mTORC1/2 dual PI3KmTOR inhibitor Failed recover reversible effect previous anticancer therapy Have receive systemic corticosteroid ( inhaler allow ) within 7 day first administration study drug Known gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance study drug Diagnosis diabetes mellitus Other clinically significant comorbidities , uncontrolled pulmonary disease , active CNS disease , active infection Known human immunodeficiency virus ( HIV ) infection Cardiovascular condition define protocol A requirement positive inotropic support ( exclude digoxin ) serious uncontrolled cardiac arrhythmia ( include atrial flutter/fibrillation ) within 1 year screening Patients take strong moderate CYP3A4 inhibitor , strong CYP2C9 CYP2C19 inhibitor clinically significant inducer CYPs 3A4 , 2C9 , 2C19 within 2 week first dose MLN0128 + MLN1117 , patient require treatment agent trial . Patients take proton pump inhibitor within 7 day first dose require treatment proton pump inhibitor trial take H2 receptor antagonist within 24 hour first dose Patients receive previous therapy PI3K inhibitor rapalogs allow study inclusion/exclusion criterion meet Diagnosis primary brain tumor symptomatic brain metastasis . Patients brain metastasis must without neurologic dysfunction would confound evaluation neurologic AEs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>MLN0128</keyword>
	<keyword>MLN1117</keyword>
</DOC>